Wednesday, October 3, 2007
Article on cnnmoney.com -- FDA tells Lilly to halt Cymbalta campaign. Here's an excerpt:
Eli Lilly has been asked to stop a Cymbalta promotion that makes misleading claims and understates risk, according to a letter sent to the drug maker by the U.S. Food and Drug Administration.
The letter said a mailer for the fast-selling drug overstates effectiveness and "omits some of the most serious and important risk information associated with its use." The letter was posted on the federal regulator's Web site.
It asked Lilly (Charts, Fortune 500) to "immediately cease" disseminating the material.